| Literature DB >> 27422939 |
Naritoshi Mukumoto1, Masao Nakayama1, Hiroaki Akasaka1, Yasuyuki Shimizu1, Saki Osuga1, Daisuke Miyawaki1, Kenji Yoshida1, Yasuo Ejima1, Yasushi Miura2, Keiji Umetani3, Takeshi Kondoh4, Ryohei Sasaki5.
Abstract
Micro-slit-beam radiation therapy (MRT) using synchrotron-generated X-ray beams allows for extremely high-dose irradiation. However, the toxicity of MRT in central nervous system (CNS) use is still unknown. To gather baseline toxicological data, we evaluated mortality in normal mice following CNS-targeted MRT. Male C57BL/6 J mice were head-fixed in a stereotaxic frame. Synchrotron X-ray-beam radiation was provided by the SPring-8 BL28B2 beam-line. For MRT, radiation was delivered to groups of mice in a 10 × 12 mm unidirectional array consisting of 25-μm-wide beams spaced 100, 200 or 300 μm apart; another group of mice received the equivalent broad-beam radiation therapy (BRT) for comparison. Peak and valley dose rates of the MRT were 120 and 0.7 Gy/s, respectively. Delivered doses were 96-960 Gy for MRT, and 24-120 Gy for BRT. Mortality was monitored for 90 days post-irradiation. Brain tissue was stained using hematoxylin and eosin to evaluate neural structure. Demyelination was evaluated by Klüver-Barrera staining. The LD50 and LD100 when using MRT were 600 Gy and 720 Gy, respectively, and when using BRT they were 80 Gy and 96 Gy, respectively. In MRT, mortality decreased as the center-to-center beam spacing increased from 100 μm to 300 μm. Cortical architecture was well preserved in MRT, whereas BRT induced various degrees of cerebral hemorrhage and demyelination. MRT was able to deliver extremely high doses of radiation, while still minimizing neuronal death. The valley doses, influenced by beam spacing and irradiated dose, could represent important survival factors for MRT.Entities:
Keywords: microbeam; neurotoxicity; radiation therapy; slit beam; synchrotron radiation
Mesh:
Year: 2016 PMID: 27422939 PMCID: PMC5321181 DOI: 10.1093/jrr/rrw065
Source DB: PubMed Journal: J Radiat Res ISSN: 0449-3060 Impact factor: 2.724
Fig. 1.Physical aspects of the experimental design. (a) A single-slit collimator which enables modulation of the peak width. Micro-slit beam dose distribution was confirmed using Gafchromic film. (b) Schematic view of the micro-slit beam dose profile in microbeam radiation therapy. (c) The total irradiation field of micro-slit beams from a ‘beam's eye view’. The field size was about 12 mm wide and 10 mm high. (d) Schematic view of the irradiation geometry for broad and micro-slit beams.
Fig. 2.The relationship between microbeam spacing and (a) peak dose, (b) valley dose, and (c) peak-to-valley dose ratio at a depth of 1 cm in a phantom. The microbeam width was 25 μm, and the spacing ranged from 50 μm to 300 μm. Peak and valley doses were measured using HD-V2 and EBT3 films, respectively. Each data point is the average of at least three measurements, and the error bars represent the standard deviation.
Fig. 3.Mortality results. (a) Mortality of mice observed for 90 days after whole brain irradiation via broad or micro-slit beams. (b) Comparison of mortalities using microbeam irradiation with different center-to-center distances (100–300 μm).
Fig. 4.Survival durations following broadbeam and microbeam irradiation plotted on Kaplan–Meier graphs.
Fig. 5.Histological analysis of cortical structure. Representative hematoxylin-eosin and Klüver-Barrera staining in (a, b) control sections; (c, d) sections taken 13 days after irradiation with a 120 Gy broadbeam; and (e, f) sections taken 90 days after irradiation with a 480 Gy micro-slit beam. All scale bars = 500 µm.